Business
Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases
Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with initial topline data anticipated in Q3 2026 Second asset, CBT-004 for the treatment of pinguecula, is Phase 3-ready following a successful End-of-Phase-2 meeting with FDA and alignment on a path forward IRVINE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Cloudbreak Pharma Inc., (HKEX 2592), a clinical stage ophthalmic drug company leveraging its proprietary Multi Kinase Inhibi
About this update from Cloudbreak Pharma, Inc.
[{"type":"image","alt":"Cloudbreak Pharma, Inc.","displaySize":"","headline":null,"caption":"Cloudbreak Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/bb8a051cebed74b0f1b519d4f6ce1ea5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IEKr.zGK9Qm0Q3HSzUNOKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ3Nw--/https://media.zenfs.com/en/globenewswire.com/bb8a051cebed74b0f1b519d4f6ce1ea5","width":264,"height":300}},"lazy":false},{"type":"text","content":"Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with initial topline data anticipated in Q3 2026","length":165,"tagName":"p"},{"type":"text","content":"Second asset, CBT-004 for the treatment of pinguecula, is Phase 3-ready following a successful End-of-Phase-2 meeting with FDA and alignment on a path forward","length":158,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Cloudbreak Pharma Inc., (HKEX 2592), a clinical stage ophthalmic drug company leveraging its proprietary Multi Kinase Inhibitor (MKI) discovery platform to develop first-in-class and best-in-class therapeutics, today announced the launch of its new website, www.cloudbreakpharma.com.","length":334,"tagName":"p"},{"type":"text","content":"The newly launched website is a critical component of Cloudbreak’s recently initiated U.S. growth strategy, designed to raise awareness of its pipeline of novel first-in-class therapeutics in development to treat serious, underserved front-of-the-eye diseases. It serves as a comprehensive resource for all stakeholders, including people with fibrovascular corneal disease, potential investors and partners, and the broader ophthalmic community, to stay informed about the company’s programs.","length":492,"tagName":"p"},{"type":"text","content":"Cloudbreak’s lead asset, the eye drop CBT-001, is in mid-Phase 3 as a potential treatment for pterygium, a potentially sight-threatening disease that impacts 15 million people in the U.S. alone. The company’s second asset, the eye drop CBT-004, is entering Phase 3 as a potential disease modifying treatment for pinguecula, which is estimated to impact half of people over the age of 70, or 50 million people in the U.S. alone. Cloudbreak is also advancing a broad pi...